Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
04/24/17

Clinical Response Rates with VIBATIV® (telavancin) Treatment Range from 58 - 75% for Patients with Complicated Skin and Skin Structure Infections, Bone and Joint Infections, or Lower Respiratory Tract Infections

04/18/17

Preliminary Data from TOUR Highlights Positive Clinical Response Rates Across Several Difficult-to-Treat Infection Types<br>Additional VIBATIV Presentations Demonstrate in vitro and in vivo Potency Against Difficult-to-Treat Staphylococcus aureus Pathogens including Challenging MRSA and MSSA Isolates

03/28/17
DUBLIN , March 28, 2017 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 , at 1:40 p.m.
02/27/17

Key Program Milestones Anticipated in 2017 and 2018

02/17/17

Further Data from Phase 1 Trial Reaffirms Favorable Tolerability of Single and Multiple Oral Doses of TD-1473 and Minimal Systemic Exposure in Healthy Subjects

02/15/17
DUBLIN , Feb. 15, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended December 31, 2016 after market close on Monday, February 27, 2017 .
02/13/17
DUBLIN , Feb. 13, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will highlight clinical data on TD-1473, a novel, potent, and orally administered pan-Janus kinase (JAK) inhibitor designed to be intestinally
02/02/17
DUBLIN , Feb. 2, 2017 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 2:00 p.m.
01/23/17

Study Results Show VIBATIV&#174; (telavancin) Generates Positive Clinical Response Rate of Approximately 65% for Patients with Bacteremia or Infective Endocarditis

01/17/17

Interim Data Highlights Positive Clinical Response Rate for VIBATIV&#174; (telavancin) in Patients with Bacteremia or Infective Endocarditis